Questions About This Book?
- The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any CDs, lab manuals, study guides, etc.
- The Used copy of this book is not guaranteed to include any supplemental materials. Typically, only the book itself is included.
- The Rental copy of this book is not guaranteed to include any supplemental materials. You may receive a brand new copy, but typically, only the book itself.
- The eBook copy of this book is not guaranteed to include any supplemental materials. Typically only the book itself is included.
The most universally respected and read medical textbook in all of pharmacology. Goodman and Gilman's represents the pinnacle of authority and accuracy in describing the actions and uses of therapeutic agents in relation to physiology and pathophysiology. It is, very much, the "Harrison's of pharmacology."Goodman and Gilman's Pharmacological Basis of Therapeuticshas sold more than 1,000,000 copies since the first edition published in 1942.
Virtually every physician and pharmacologist and pharmacist in the US, and many throughout the world, has at some point relied upon G&G to present the most authoritative, accurate, and useful coverage the basic and clinical aspects of chemical therapeutics. The book is a great strategic fit with our domestic and global product lines in virtually all categories and specialties, and its enormous credibility carries over to the benefit our entire publishing program.
Used equally in its life as a textbook and as a reference book, in recent editions G&G has settled into its role as the undisputed heavyweight of pharmacology reference information, purchased by medical and scientific libraries, pharmacologists, toxicologists, clinicians, and departmental libraries within hospitals and medical schools.
The 11th edition published in August, 2005. In that time it has sold more than 55,000 units, the majority of those being sold outside the US. The streamlined page count, modernized text design, and updated coverage have been well received. The most important innovation, and one that will continue to be very relevant to future editions, has been the development and launch of Goodman and Gilman On Line.
G&G is in many ways the perfect medical book to be converted to and driven by the On Line format, given the breadth and depth of new information in pharmacology and drug therapy, and given the contributions multimedia materials can make to the subject of clinical pharmacology. In addition, the pairing of G&G with a detailed therapeutics/dosing database on Access Medicine is an important and valuable feature.
The 12th edition of G&G will continue to be under the command of Laurence Brunton, PhD, and Keith Parker, MD PhD. We have identified several new and revised features and priorities for the new edition:
Key Selling Features :
-Brand new: for the first time ever, G&G will feature a full-color format with greatly improved text design to aid reader navigation and great new illustrations showing more detail than ever before possible in the book. The illustrations will be a major feature of the on line version of G&G, as well.
-Brand new: the 12th edition features a DVD image bank for the first time, allowing users to seamlessly employ graphics from the book in lectures and presentations.
-Brand new: The DVD also includes the excellent pedagogical animations from Goodman and Gilman On Line. These animations brilliantly display complex pharmacological concepts in a clear manner that enhances understanding.
-Expanded: The 12th edition will feature more illustrations than ever before, with approximately 200 additional figures showing key principles and actions of specific pathways and therapeutic agents.
-Modernized and revamped: G&G 12 will feature a brand new text design with the many different elements and parts of chapters receiving a unique and consistent design for ease of reference and navigation.
-Reorganized: the classic Goodman and Gilman structure will be retained, but with notable improvements in the organization of specific sections. Cardiovascular and renal therapeutics will now be covered in different sections. Cancer therapeutics, traditionally one huge chapter in G&G, will be broken out into multiple chapters, with a particular emphasis on the new targeted anti-tumor therapies. The lengthy section on the pharmacology of anti-microbials will be streamlined.
"This 12th edition of the most authoritative book in pharmacology is the best both in content and physical appearance....This edition of Goodman & Gilman's continues to be the most authoritative and widely used resource bridging the discipline of pharmacology with therapeutics. Moreover, readers will find this edition to be substantially improved from past editions in both content and physical appearance."-Doody's Review Service
Laurence Brunton, PhD, is Professor of Pharmacology and Professor of Medicine, UCSD School of Medicine, San Diego, CA.
Keith Parker, MD PhD is Professor of Medicine, and Director of Endocrinology, at the UTSouthwestern School of Medicine, Dallas TX.
Table of Contents
Consultants to the Editors
Preface to the First Edition
SECTION I: GENERAL PRINCIPLES
1. Drug Invention and the Pharmaceutical Industry, Suzanne M. Rivera and Alfred Goodman Gilman
2. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination, Iain L. O. Buxton and Leslie Z. Benet
3. Pharmacodynamics: Molecular Mechanisms of Drug Action, Donald K. Blumenthal and James C. Garrison
4. Drug Toxicity and Poisoning, Kevin C. Osterhoudt and Trevor M. Penning
5. Membrane Transporters and Drug Response, Kathleen M. Giacomini and Yuichi Sugiyama
6. Drug Metabolism, Frank J. Gonzalez, Michael Coughtrie, and Robert H. Tukey
7. Pharmacogenetics, Mary V. Relling and Kathleen M. Giacomini
SECTION II: NEUROPHARMACOLOGY
8. Neurotransmission: The Autonomic and Somatic Motor Nervous Systems, Thomas C. Westfall and David P. Westfall
9. Muscarinic Receptor Agonists, Joan Heller Brown and Nora Laiken
10. Anticholinesterase Agents, Palmer Taylor
11. Agents Acting at the Neuromuscular Junction and Autonomic Ganglia, Ryan E. Hibbs and Alexander C. Zambon
12. Adrenergic Agonists and Antagonists, Thomas C. Westfall and David P. Westfall
13. 5-Hydroxytryptamine (Serotonin) and Dopamine, Elaine Sanders-Bush and Lisa Hazelwood
14. Neurotransmission and the Central Nervous System, Perry B. Molinoff
15. Drug Therapy of Depression and Anxiety Disorders, James M. O'Donnell and Richard C. Shelton
16. Pharmacotherapy of Psychosis and Mania, Jonathan M. Meyer
17. Hypnotics and Sedatives, S. John Mihic and r. Adron Harris
18. Opioids, Analgesia, and Pain Management, Tony L. Yaksh and Mark S. Wallace
19. General Anesthetics and Therapeutic Gases, Piyush M. Patel, Hemal H. Patel, and David M. Roth
20. Local Anesthetics, William A. Catteral nad Kenneteh Mackie
21. Pharmacotherapy of the Epilepsies, James O. McNamara
22. Treatment of Central Nervous System Degenerative Disorders, David G. Standaert and Erik D. Roberson
23. Ethanol and Methanol, Marc A. Schuckit
24. Drug Addition, Charles P. O'Brien
SECTION III: MODULATION OF CARDIOVASCULAR FUNCTION
25. Regulation of Renal Function and Vascular Volume, Robert F. Reilly and Edwin K. Jackson
26. Renin and Angiotensin, Randa Hilal-Dandan
27. Treatment of Myocardial Ischemia and Hypertension, Thomas Michel and Brian B. Hoffman
28. Pharmacotherapy of Congestive Heart Failure, Bradley A. Maron and Thomas P. Rocco
29. Anti-Arrhythmic Drugs, Kevin J. Sampson and Robert S. Kass
30. Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs, Jeffrey I. Weitz
31. Drug Therapy for Hypercholesterolemia and Dyslipiedmia, Thomas P. Bersot
SECTION IV: INFLAMMATION, IMMUNOMODULATION, AND HEMATOPOIESIS
32. Histamine, Bradykinin, and Their Antagonists, Randal A. Skidgel, Allen P. Kaplan, and Ervin G. Erdös
33. Lipid-Derived Autacoids: Eicosanoids and Platelet-Activating Factor, Emer M. Smyth, Tilo Grosser, and Garret A. Fitzgerald
34. Anti-inflammatory, Antipyretic, and Analgesic Agents; Pharmacology of Gout, Tilo Grosser, Emer Smyth, and Garret A. FitzGerald
35. Immunosupressants, Tolerogens, and Immunostimulants, Alan M. Krensky, William M. Bennett, and Flavio Vincenti
36. Pulmonary Pharmacology, Peter J. Barnes
37. Hematopoietic Agents: Growth Factors, Minerals, and Vitamins, Kenneth Kaushansky and Thomas J. Kipps
SECTION V: HORMONES AND HORMONE ANTAGONISTS
38. Introduction to Endocrinology: The Hypothalamic-Pituitary Axis, Keith L. Parker and Bernard P. Schimmer
39. Thyroid and Anti-Thyroid Drugs, Gregory A. Brent and Ronald J. Koenig
40. Estrogens and Progestins, Ellis R. Levin and Stephen R. Hammes
41. Androgens, Peter J. Snyder
42. ACTH, Adrenal Steroids, and Pharmacology of the Adrenal Cortex, Bernard P. Schimmer and John W. Funder
43. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia, Alvin C. Powers and David D'Alessio
44. Agents Affecting Mineral Ion Homeostatis and Bone Turnover, Peter A. Friedman
SECTION VI: DRUGS AFFECTING GASTROINTESTINAL FUNCTION
45. Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease, John L. Wallace and Keith A. Sharkey
46. Treatment of Disorders of Bowel Motility and Water Flux: Anti-Emetics; Agents Used in Biliary and Pancreative Disease, Keith A. Sharkey and John L. Wallace
47. Pharmacotherapy of Inflammatory Bowel Disease, John L. Wallace and Keith A. Sharkey
SECTION VII: CHEMOTHERAPY OF MICROBIAL DISEASES
48. General Principles of Antimicrobial Therapy, Tawanda Gumbo
49. Chemotherapy of Malaria, Joseph M. Vinetz, Jerome Clain, Viengngeun Bounkeua, Richard T. Eastman, and David Fidock
50. Chemotherapy of Protozoal Infections: Amebiasis, Giardiasis, Trichomoniasis, Trypanosomiasis, Leishmaniasis, and Other Protozoal Infections, Margaret A. Phillips, Samuel L. Stanley, Jr.
51. Chemotherapy of Helminth Infections, James McCarthy, Alex Loukas, and Peter J. Hotez
52. Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and Agents for Urinary Tract Infections, William A. Petri, Jr.
53. Penicillins, Cephalosporins, and Other ß-Lactam Antibiotics, William A. Petri, Jr.
54. Aminoglycosides, Conan MacDougall and Henry F. Chambers
55. Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents, Conan MacDougall and Henry F. Chambers
56. Chemotherapy of Tuberculosis, Mycobacterium Avium Complex Disease, and Leprosy, Tawanda Gumbo
57. Antifungal Agents, John E. Bennett
58. Antiviral Agents (Nonretroviral), Edward P. Acosta and Charles Flexner
59. Antiretroviral Agents and Treatment of HIV Infection, Charles Flexner
SECTION VIII: CHEMOTHERAPY OF NEOPLASTIC DISEASES
60. General Principles of Cancer Chemotherapy, Bruce A. Chabner
61. Cytotoxic Agents, Bruce A. Chabner, Joseph Bertino, James Cleary, Taylor Ortiz, Andrew Lane, Jeffrey G. Supko, and David Ryan
62. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines, Bruce A. Chabner, Jeffrey Barnes, Joel Neal, Erin Olson, Hamza Mujagic, Lecia Sequist, Wynham Wilson, Dan L. Longo, Constantine Mitsiades, and Paul Richardson
63. Natural Products in Cancer Chemotherapy: Hormones and Related Agents, Beverly Moy, Paul Goss, Richard J. Lee, and Matthew Smith
SECTION IX: OPHTHALMOLOGY
64. Ocular Pharmacology, Jeffrey D. Henderer and Christopher J. Rapuano
65. Dermatological Pharmacology, Craig Burkhart, Dean Morrell, and Lowell Goldsmith
66. Contraception and Pharmacotherapy of Obstetrical and Gynecological Disorders, Bernard P. Schimmer and Keith L. Parker
67. Environmental Toxicology: Carcinogens and Heavy Metals, Michael C. Byrns and Trevor M. Penning
I. Principles of Prescription Order Writing and Patient Compliance, Iain L.O. Buxton
II. Design and Optimization of Dosage Regimens: Pharmacokinetic Data, Kenneth E. Thummel, Danny D. Shen, and Nina Isoherranen